-
Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection
-
Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy
-
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
-
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
-
Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
-
No PFS, OS Benefit Seen in Final Results from PACIFIC-2
-
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
-
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
-
A Holistic Approach to Patient Care
Sign up for news updates
-
The Weight of Shame
Advocate Terri Ann DiJulio knows the stigma associated with smoking must end if more lung cancer patients are to be diagnosed and treated early. The first step is talking about it.
-
Amivantamab Demonstrates Consistent Efficacy in CHRYSALIS Follow-up
Spain’s Dr. Pilar Garrido reviews long-term efficacy, safety, and predictors-of-response data for post-platinum advanced NSCLC patients with EGFR exon 20 insertion mutations.
-
Early Detection Researcher Shares Epidemiologic Evidence on Air Pollution, Lung Cancer
Dr. Christine Berg says both smoking and air pollution are important in causing lung cancer. And both need to be eliminated to help prevent it and save lives.
-
Analysis Shows Cancer Death Rates Must Decline Faster to Reach ‘Moonshot’ Goal
A team of NCI researchers recently investigated what needs to happen for the United States to reach President Biden’s goal of cutting cancer mortality by 50% by 2047.
-
Histologic Evaluation of Lung Cancer Invasion: More Difficult Than Meets the Eye
IASLC Pathology Committee members say the identification and evaluation of features that result in discordance in measuring invasive tumor size will hopefully improve reproducibility and lead to more accurate tumor staging moving forward.
-
Primary AEGEAN Analysis Shows Improved EFS, pCR with Periadjuvant Durvalumab
Investigator Dr. John Heymach says the positive phase 3 data may lead to a potential new treatment option for patients with resectable NSCLC.
-
Investigator Shares Findings That Point to Possible Mechanism of SCLC Plasticity
During IASLC’s 2023 Hot Topic Meeting on small cell lung cancer, Dr. Trudy Oliver discussed how MYC genes drive the evolution of SCLC subtypes.
-
Closing Keynote Highlights Progress, Challenges in Management of SCLC
From new diagnostic approaches to new evidence on the potential mechanisms of treatment resistance, Dr. Charles M. Rudin looked back on how small cell research has evolved and what needs remain.
-
In Brief for April 26, 2023
US Food and Drug Administration grants Fast Track designation for novel mesothelioma therapy.
-
IASLC Staging Project Finalizing Recommendations for 9th Edition of TNM Classification System
In a recent interview, Staging and Prognostic Factors Committee Chair Dr. Hisao Asamura provides an update on efforts to further refine the system.
View ILCN Archives
Provider Resources
Popular Articles